Table 2.

The aPL and other laboratory profiles of the patients

	Low titers (n = 92)	Medium–high titers (n = 32)	P
aβ2GP1-IgG positive	3 (3.3%)	13 (40.6%)	< 0.001
aβ2GP1-IgM positive	13 (14.1%)	10 (31.3%)	0.032
ACL-IgG positive	9 (9.8%)	7 (21.9%)	0.147
ACL-IgM positive	75 (81.5%)	12 (37.5%)	< 0.001
LA positive	3 (3.8%)	2 (7.4%)	0.812
Single positive	83 (90.2%)	26 (81.3%)	0.305
Double positive	9 (9.8%)	4 (12.5%)	0.923
Triple positive	0 (0%)	2 (6.3%)	0.109
ANA positive	12/76 (15.8%)	7/28 (25%)	0.281
Anti-SSA antibody positive	7/72 (9.7%)	3/27 (11.1%)	1.000
Anti-SSB antibody positive	0 (0%)	1/27 (3.7%)	0.614
TGAb positive	5/75 (6.7)	1/27 (3.7%)	0.933
TPOAb positive	9/75 (12)	3/27 (11.1%)	1.000
IgG (g/L)	12.28 ± 2.14	13.24 ± 2.40	0.707
IgA (g/L)	2.28 (1.91, 2.75)	2.90 (1.87, 3.31)	0.445
IgM (g/L)	2.06 ± 0.86	1.93 ± 0.79	0.072
C3 (g/L)	1.17 (1.10, 1.31)	1.33 (1.18, 1.50)	0.124
C4 (g/L)	0.22 (0.18, 0.29)	0.26 (0.15, 0.31)	0.566
CRP (mg/L)	0.75 (0.33, 2.45)	3.26 (2.47, 5.11)	0.144
ESR (mm/h)	11 (5, 16)	19.5 (11.77, 25)	0.006

aβ2GP1 anti-β2-glycoprotein 1 antibodies, aCL anticardiolipin antibodies, LA lupus anticoagulants, ANA antinuclear antibody, TGAb thyroglobulin autoantibodies, TPOAb anti-thyroperoxidase antibodies, ESR erythrocyte sedimentation rate, CRP C-reactive protein